Reven’s Co-Founder Michael Volk Appears on Cheddar News
WESTMINSTER, Colo.--(BUSINESS WIRE)--Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19—and inflammatory disorders, yesterday co-founder Michael Volk appeared on Cheddar News (40 million pay-tv households) to discuss the future of medicine. In this national broadcasted interview, Mr. Volt shared the company’s goals to bring their flagship platform drug Rejuveinix (RJX) to market.
Cheddars’s Alicia Nieves asked “RJX I want to delve a little bit more into this because it seems just pretty fascinating to me it has a wide range of uses, how common or uncommon, is that in this industry and is that a disruptor in terms of pharmaceuticals?
Mr. Volk responded “We believe we're positioned very well to be a disruptor. We are best at the moment, and where science works for best applied as an adjunct therapy to current standards of care. There are a number of really great medications out there are phenomenal drugs that have been developed for different diseases, and a lot of people unfortunately can't take them because of the side-effects. Some people, the side effects aren't bad enough where, you know, they can still take benefit from it. RJX given in conjunction with a lot of these drugs may have a profound and anti-inflammatory effect.
Which then reduces the propensity for a lot of these other ailments to happen. So, we don't want to say we're a cure for everything we don't want to say, we eliminate this disease or that disease, but what we can say with a very high degree of confidence in our clinical data shows is that the anti-inflammatory properties of RJX are very compelling.
We treat inflammation far better than what steroids or corticosteroids can do, which are oftentimes detrimental to the immune system in the body. So, overall, if we get engaged. Any, I guess any disease rooted in inflammation, we would be a good fit to treat.”
About Rejuveinix (RJX)
RJX is an intravenous (IV) formulation of known physiologically compatible compounds that is being developed for more effective supportive therapy of patients with sepsis, including COVID-19 patients with viral sepsis and acute respiratory distress syndrome (ARDS). RJX is a proprietary composition of naturally occurring antioxidants and anti-inflammatory agents which, in combination, provide potent and immediate tissue protection. The components of RJX exhibited promising activity in clinical studies involving ARDS patients and/or non-clinical studies in animal models of ARDS. The published data from these clinical and non-clinical studies provided the medical-scientific rationale for Reven’s clinical development strategy for RJX and a clinical study in COVID-19 patients. The clinical tolerability of RJX was confirmed in a recently completed double blind, placebo-controlled Phase 1 dose-escalation study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105).
About Reven Holdings, Inc.
Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado based operating company Reven, LLC, is a biopharmaceutical company. Reven’s vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.
Reven’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “on-track”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, “estimate,” “intend,” “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various disease indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing market competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes. These risks are not exhaustive; the company faces known and unknown risks, including the risk factors described in the company’s periodic SEC filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information regarding future events, or otherwise.
Peter Lange, Chief Executive Officer | 941-320-9271 Peter.Lange@reven.com
Brian Denomme, President | 743-255-1123 Brian.Denomme@reven.com
Michael Volk, Chief Strategy Officer | 303-669-1336 Michael.Volk@reven.com
Dan Hoffman, Chief Operating Officer | 212-920-1932 Daniel.Hoffman@reven.com
Jeff Halverson, Chief Financial Officer | 970-376-8842 Jeff.Halverson@reven.com